Search

Your search keyword '"Lindqvist, Ebba K."' showing total 37 results
Start Over Author "Lindqvist, Ebba K."
37 results on '"Lindqvist, Ebba K."'

2. Current clinical practice in the management of phyllodes tumors of the breast: an international cross-sectional study among surgeons and oncologists

Author

Sars, Carl, Sackey, Helena, Frisell, Jan, Dickman, Paul W., Karlsson, Fredrik, Kindts, Isabelle, Marta, Gustavo Nader, Freitas-Junior, Ruffo, Tvedskov, Tove Filtenborg, Kassem, Loay, Ali, Ahmed S., Ihalainen, Hanna, Neron, Mathias, Kontos, Michalis, Kaidar-Person, Orit, Meattini, Icro, Francken, Anne Brecht, van Duijnhoven, Frederieke, Moberg, Ingvild Ona, Marinko, Tanja, Kollar, Attila, Ahmed, Mahbubl, Remoundos, Dennis, Banks, Jenny, Jagsi, Reshma, Dossett, Lesly A., and Lindqvist, Ebba K.

Published
2023
Full Text
View/download PDF

6. Current clinical practice in the management of phyllodes tumors of the breast:an international cross-sectional study among surgeons and oncologists

Author

Sars, Carl, Sackey, Helena, Frisell, Jan, Dickman, Paul W., Karlsson, Fredrik, Kindts, Isabelle, Marta, Gustavo Nader, Freitas-Junior, Ruffo, Tvedskov, Tove Filtenborg, Kassem, Loay, Ali, Ahmed S., Ihalainen, Hanna, Neron, Mathias, Kontos, Michalis, Kaidar-Person, Orit, Meattini, Icro, Francken, Anne Brecht, van Duijnhoven, Frederieke, Moberg, Ingvild Ona, Marinko, Tanja, Kollar, Attila, Ahmed, Mahbubl, Remoundos, Dennis, Banks, Jenny, Jagsi, Reshma, Dossett, Lesly A., Lindqvist, Ebba K., Sars, Carl, Sackey, Helena, Frisell, Jan, Dickman, Paul W., Karlsson, Fredrik, Kindts, Isabelle, Marta, Gustavo Nader, Freitas-Junior, Ruffo, Tvedskov, Tove Filtenborg, Kassem, Loay, Ali, Ahmed S., Ihalainen, Hanna, Neron, Mathias, Kontos, Michalis, Kaidar-Person, Orit, Meattini, Icro, Francken, Anne Brecht, van Duijnhoven, Frederieke, Moberg, Ingvild Ona, Marinko, Tanja, Kollar, Attila, Ahmed, Mahbubl, Remoundos, Dennis, Banks, Jenny, Jagsi, Reshma, Dossett, Lesly A., and Lindqvist, Ebba K.

Abstract

Purpose: Phyllodes tumors of the breast are rare fibroepithelial lesions that are classified as benign, borderline or malignant. There is little consensus on best practice for the work-up, management, and follow-up of patients with phyllodes tumors of the breast, and evidence-based guidelines are lacking. Methods: We conducted a cross-sectional survey of surgeons and oncologists with the aim to describe current clinical practice in the management of phyllodes tumors. The survey was constructed in REDCap and distributed between July 2021 and February 2022 through international collaborators in sixteen countries across four continents. Results: A total of 419 responses were collected and analyzed. The majority of respondents were experienced and worked in a university hospital. Most agreed to recommend a tumor-free excision margin for benign tumors, increasing margins for borderline and malignant tumors. The multidisciplinary team meeting plays a major role in the treatment plan and follow-up. The vast majority did not consider axillary surgery. There were mixed opinions on adjuvant treatment, with a trend towards more liberal regiments in patients with locally advanced tumors. Most respondents preferred a five-year follow-up period for all phyllodes tumor types. Conclusions: This study shows considerable variation in clinical practice managing phyllodes tumors. This suggests the potential for overtreatment of many patients and the need for education and further research targeting appropriate surgical margins, follow-up time and a multidisciplinary approach. There is a need to develop guidelines that recognize the heterogeneity of phyllodes tumors.

Published
2023

18. Dietary intake is associated with risk of multiple myeloma and its precursor disease

Author

Thordardottir, Marianna, primary, Lindqvist, Ebba K., additional, Lund, Sigrun H., additional, Costello, Rene, additional, Burton, Debra, additional, Steingrimsdottir, Laufey, additional, Korde, Neha, additional, Mailankody, Sham, additional, Eiriksdottir, Gudny, additional, Launer, Lenore J., additional, Gudnason, Vilmundur, additional, Harris, Tamara B., additional, Landgren, Ola, additional, Torfadottir, Johanna E., additional, and Kristinsson, Sigurdur Y., additional

Published
2018
Full Text
View/download PDF

19. Bone disease in monoclonal gammopathy of undetermined significance: results from a screened population-based study

Author

Thorsteinsdottir, Sigrun, primary, Lund, Sigrun H., additional, Lindqvist, Ebba K., additional, Thordardottir, Marianna, additional, Sigurdsson, Gunnar, additional, Costello, Rene, additional, Burton, Debra, additional, Steingrimsdottir, Hlif, additional, Gudnason, Vilmundur, additional, Eiriksdottir, Gudny, additional, Siggeirsdottir, Kristin, additional, Harris, Tamara B., additional, Landgren, Ola, additional, and Kristinsson, Sigurdur Y., additional

Published
2017
Full Text
View/download PDF

20. Obesity and risk of monoclonal gammopathy of undetermined significance and progression to multiple myeloma: a population-based study

Author

Thordardottir, Marianna, primary, Lindqvist, Ebba K., additional, Lund, Sigrun H., additional, Costello, Rene, additional, Burton, Debra, additional, Korde, Neha, additional, Mailankody, Sham, additional, Eiriksdottir, Gudny, additional, Launer, Lenore J., additional, Gudnason, Vilmundur, additional, Harris, Tamara B., additional, Landgren, Ola, additional, and Kristinsson, Sigurdur Y., additional

Published
2017
Full Text
View/download PDF

21. Risk of Progression in Monoclonal Gammopathy of Undetermined Significance (MGUS): Results from a Population-Based Screening Study

Author

Lindqvist, Ebba K, primary, Lund, Sigrun H, additional, Costello, Rene, additional, Burton, Debra, additional, Korde, Neha S, additional, Mailankody, Sham, additional, Björkholm, Magnus, additional, Eiriksdottir, Gudny, additional, Launer, Leonore J, additional, Harris, Tamara B, additional, Hultcrantz, Malin, additional, Gudnason, Vilmundur, additional, Landgren, Ola, additional, and Kristinsson, Sigurdur Y, additional

Published
2016
Full Text
View/download PDF

22. Dietary Pattern and Risk of Monoclonal Gammopathy of Undetermined Significance: A Population-Based Study

Author

Thordardottir, Marianna, primary, Lindqvist, Ebba K, additional, Lund, Sigrun H, additional, Costello, Rene, additional, Torfadottir, Johanna E, additional, Birgisdottir, Bryndis E, additional, Burton, Debra, additional, Steingrimsdottir, Laufey, additional, Korde, Neha S, additional, Mailankody, Sham, additional, Eiriksdottir, Gudny, additional, Launer, Lenore J, additional, Harris, Tamara B, additional, Landgren, Ola, additional, Gudnason, Vilmundur, additional, and Kristinsson, Sigurdur Y, additional

Published
2016
Full Text
View/download PDF

25. Monoclonal gammopathy of undetermined significance : natural course and comorbidities

Author

Lindqvist, Ebba K and Lindqvist, Ebba K

Abstract

Monoclonal gammopathy of undetermined significance (MGUS) is a plasma cell disorder characterized by an overproduction of monoclonal immunoglobulins. MGUS is asymptomatic but clinically relevant since annually 0.5-1.5% of individuals with MGUS will develop multiple myeloma (MM) or another malignant lymphoproliferative disease. Individuals with MGUS are followed for signs of progression, however, so far this management strategy has never been evaluated. Results from previous studies have shown that individuals with MGUS have inferior survival and increased risk of thrombosis compared to individuals without MGUS, yet all studies to date have been performed on clinically established cohorts of MGUS patients, introducing a high risk of selection bias. Recently, a new entity called light-chain MGUS (LC-MGUS) has been identified. Very little is known about the epidemiology and clinical course of LC-MGUS. In order to establish a clinically informative, correct, and easily applicable definition of LC-MGUS, and describe the prevalence of MGUS and LC-MGUS in the population, we performed a large population-based screening study. We screened more than 11,000 individuals from the Icelandic AGES-Reykjavik Study cohort and the American PLCO Study cohort. The prevalence of MGUS was 4.8-5.2%. Based on findings from the two cohorts and on statistical analysis of normal distributions, we propose a revised definition of LC-MGUS; (1) an abnormal free light-chain ratio (<0.26 or >1.65), (2) an elevated involved light chain concentration (40 mg/L or higher), (3) no M-protein on serum protein electrophoresis or immunofixation, and (4) no evidence of end-organ damage that can be attributed to a lymphoproliferative disorder. The prevalence of LC-MGUS in our study using this definition was 0.9-1.0%. The prevalence of LC-MGUS increased with age (p<0.001), was higher in men (p<0.001), and more common among blacks (2.9%) than whites (0.7%) or Asian/Pacific Islanders (0.2%). The revised definitio

Published
2016

28. No Risk of Arterial or Venous Thrombosis in Monoclonal Gammopathy of Undetermined Significance: Results from a Population-Based Study

Author

Lindqvist, Ebba K, primary, Lund, Sigrún H., additional, Costello, Rene, additional, Burton, Debra, additional, Korde, Neha S, additional, Mailankody, Sham, additional, Gudnason, Vilmundur, additional, Eiriksdottir, Gudny, additional, Launer, Leonore, additional, Harris, Tamara B, additional, Hultcrantz, Malin, additional, Landgren, Ola, additional, Kristinsson, Sigurdur Y, additional, and Bjorkholm, Magnus, additional

Published
2015
Full Text
View/download PDF

29. Obesity and Risk of Monoclonal Gammopathy of Undetermined Significance: A Population-Based Study

Author

Thordardottir, Marianna, primary, Lund, Sigrun Helga, additional, Lindqvist, Ebba K, additional, Costello, Rene, additional, Burton, Debra, additional, Korde, Neha, additional, Mailankody, Sham, additional, Eiriksdottir, Gudny, additional, Launer, Lenore J, additional, Gudnason, Vilmundur, additional, Harris, Tamara B, additional, Landgren, Ola, additional, and Kristinsson, Sigurdur Y, additional

Published
2014
Full Text
View/download PDF

30. History of autoimmune disease is associated with impaired survival in multiple myeloma and monoclonal gammopathy of undetermined significance: a population-based study.

Author

Hultcrantz, Malin, Kristinsson, Sigurdur, Lindqvist, Ebba, Björkholm, Magnus, Landgren, Ola, Lund, Sigrún, Turesson, Ingemar, Goldin, Lynn, Lindqvist, Ebba K, Lund, Sigrún H, Björkholm, Magnus, and Kristinsson, Sigurdur Y

Subjects
AUTOIMMUNE diseases, MULTIPLE myeloma, MONOCLONAL gammopathies, SURVIVAL analysis (Biometry), CONFIDENCE intervals, POPULATION genetics, DISEASE risk factors, AUTOIMMUNE disease diagnosis, MULTIPLE myeloma diagnosis, LONGITUDINAL method, PUBLIC health surveillance, SURVIVAL, DIAGNOSIS
Abstract

Multiple myeloma (MM) is a plasma cell disorder preceded by monoclonal gammopathy of undetermined significance (MGUS). Incidence of MM and MGUS is higher among patients with autoimmune disease. The aim of this study was to determine whether a history of autoimmunity has an impact on survival in MM and MGUS. Using high-quality national Swedish registries, we identified 8367 patients with MM, 18,768 patients with MGUS, and 110,251 matched control subjects, and obtained information on previous autoimmune disease in patients and controls. Cox regression was used to calculate hazard ratios (HRs) for overall survival with 95 % confidence intervals (CIs). In patients with MM and a prior autoimmune disease, the risk of death was significantly increased, HR = 1.2 (95 % CI 1.2-1.3) compared to MM patients with no history of autoimmunity. In MGUS patients, a prior autoimmune disease was associated with a significantly 1.4-fold elevated risk of death (95 % CI 1.3-1.4). When analyzing different types of autoimmune diseases, a history of ulcerative colitis had a stronger impact on survival in MM than in controls. Our findings that a history of autoimmune disease has a negative impact on survival in MM and MGUS could be due to shared underlying common genetic factors, or that patients with a history of autoimmunity develop more severe cases of MM and MGUS, or cumulative comorbidity in the individual. Our results suggest that more attention should be paid to comorbidity as a prognostic factor in MGUS and MM, and underlines the need for studies aimed at tailoring therapy according to comorbidity. [ABSTRACT FROM AUTHOR]

Published
2017
Full Text
View/download PDF

34. Personal and family history of immune-related conditions increase the risk of plasma cell disorders : a population-based study

Author

Lindqvist, Ebba K., Goldin, Lynn R., Landgren, Ola, Blimark, Cecilie, Mellqvist, Ulf-Henrik, Turesson, Ingemar, Wahlin, Anders, Björkholm, Magnus, Kristinsson, Sigurdur Y., Lindqvist, Ebba K., Goldin, Lynn R., Landgren, Ola, Blimark, Cecilie, Mellqvist, Ulf-Henrik, Turesson, Ingemar, Wahlin, Anders, Björkholm, Magnus, and Kristinsson, Sigurdur Y.

Abstract

The associations between immune-related conditions and multiple myeloma (MM) and monoclonal gammopathy of undetermined significance (MGUS) have previously been investigated with inconsistent results. In a large population-based study, we identified 19 112 patients with MM, 5403 patients with MGUS, 96 617 matched control subjects, and 262 931 first-degree relatives. We calculated odds ratios (ORs) and 95% confidence intervals (CIs) for the association of MM and MGUS with immune-related conditions by use of logistic regression. A personal history of all infections combined was associated with a significantly increased risk of MM (OR = 1.2; 95% CI, 1.1-1.3), and a personal history of all conditions in the categories infections (OR = 1.6; 95% CI, 1.5-1.7), inflammatory conditions (OR = 1.4; 95% CI, 1.2-1.5), and autoimmune diseases (OR = 2.1; 95% CI, 1.9-2.4) was associated with a significantly increased risk of MGUS. Several specific immune-related conditions elevated the risk of MM and/or MGUS. A family history of autoimmune disease was associated with a significantly increased risk of MGUS (OR = 1.1; 95% CI, 1.00-1.2), but not MM. Our findings suggest that immune-related conditions and/or their treatment are of importance in the etiology of MGUS and possibly MM. The association of both personal and family history of autoimmune disease with MGUS indicates the potential for shared susceptibility for these conditions. (Blood. 2011; 118(24): 6284-6291)

Published
2011
Full Text
View/download PDF

36. Incidence and risk factors for suicide and attempted suicide following a diagnosis of hematological malignancy.

Author

Hultcrantz, Malin, Svensson, Tobias, Derolf, Åsa R., Kristinsson, Sigurdur Y., Lindqvist, Ebba K., Ekbom, Anders, Granath, Fredrik, and Björkholm, Magnus

Subjects
SUICIDE risk factors, SUICIDAL behavior, HEMATOLOGIC malignancies, MULTIPLE myeloma, ONCOLOGY
Abstract

Solid tumors are associated with an increased risk of suicide, however, there is limited detailed information on the risk of suicide in patients with hematological malignancies. Therefore, we conducted a population-based study including 47,220 patients with hematological malignancies (diagnosed 1992-2006) and their 235,868 matched controls to define the incidence and risk factors for suicide and suicide attempt. Information on suicides, suicide attempts, and preexisting psychiatric disorders was obtained from Swedish registers and individual medical records. There was a twofold increased (hazard ratio [HR] = 1.9, 95% confidence interval 1.5-2.3, P < 0.0001) risk of suicide/suicide attempt during the first 3 years after diagnosis in patients with hematological malignancies compared to matched controls. Of all hematological malignancies, multiple myeloma was associated with the highest risk (HR = 3.4; 2.3-5.0, P < 0.0001). Patients with a preexisting psychiatric disorder were at a very high risk of suicide and suicide attempt (HR = 23.3; 16.6-32.6, P < 0.0001), regardless of type of hematological malignancy. Among patients who committed suicide, 19% were in a palliative phase and 44% were in remission with no active treatment. In conclusion, the risk of suicide and suicide attempt is elevated in patients with hematological malignancies. Certain high-risk patients may benefit from early detection and preventive measures. [ABSTRACT FROM AUTHOR]

Published
2015
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results